Epilepsy sales boost Cyberonics' Q2
This article was originally published in Clinica
Cyberonics said revenue for the second fiscal quarter increased 24% to $36m, as the neuromodulation device company benefited from the continued growth in its core epilepsy business. US sales of its vagus nerve stimulation therapy device for treating epilepsy leapt 32% to $28.6m, while international sales of the product increased a more modest 12% to $6.6m due to negative impact of foreign currency movements. The Houston, Texas firm also swung into profit during the period, recording a net income of $8.35m, which included a gain of $4.61m on early extinguishment of debt. Even when earnings were adjusted to exclude this one-time gain, Cyberonics still saw a net profit of $3.74m, a significant improvement over the net loss of $4.08m recorded in the same quarter last year. The robust results reflect the success of the company's strategy to turn its fortune s around by shifting its focus away from its anti-depression device and channelling its efforts into on growing the its epilepsy business. Encouraged by its strong performance in the first half of the year, Cyberonics upped its fiscal 2009 sales guidance to $136-140m. sinto the
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.